Details of the Drug-Related molecule(s) Interaction Atlas

Maleimides derivative 3 Drug Info

PMID27828716-Compound-SB415286

Cross-matching ID

TTD Drug ID

DMEFQND

General Information of Drug (ID: DMEFQND)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Glycogen synthase kinase-3 alpha (GSK-3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[2]
LY2090314	DMTBFE4	Acute myeloid leukaemia	2A60	Phase 2	[1]
Lithium	DMZ3OU6	Bipolar disorder	6A60	Phase 2	[3]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[1]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[1]
TDZD-8	DMG6Q45	Malignant glioma	2A00.0	Patented	[1]
AR-A014418	DMUPN01	Ovarian cancer	2C73	Patented	[1]
PMID27828716-Compound-21	DMO1NAR	N. A.	N. A.	Patented	[1]
Thiadiazolidindione derivative 2	DM5AUL0	N. A.	N. A.	Patented	[1]
PMID27828716-Compound-18	DMNR6KL	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycogen synthase kinase-3 alpha (GSK-3A)	TTRZQE3	GSK3A_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
2	Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76.
3	The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.